Study on the Cell Wall Skeleton Derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) : Establishment of Preparation and Analytical Methods
スポンサーリンク
概要
- 論文の詳細を見る
Mycobacterial cell walls have diverse adjuvant activities, and in particular, cell wall skeleton (CWS) of Mycobacterium bovis BCG has been expected as a drug for tumor immunotherapy. However, its molecular structure-biological activity relationship has not been fully elucidated despite more than 30 years of intensive research. Since it is important to secure purified CWS for such investigation, we established a preparation method of CWS from M. bovis BCG Tokyo 172 (SMP-105) and developed accurate, precise, and reliable analytical methods, based on previous reports. Furthermore, we confirmed that SMP-105 is composed of mycolic acids; arabinogalactan consisting of arabinose, galactose, and rhamnose; and peptidoglycan consisting of alanine, glutamic acid, diaminopimeric acid, muramic acid, glucosamine, and galactosamine. We also determined the levels of potential impurities that might be contaminated in the original bacterium or arise during the manufacturing process, such as glucose, mannose, non-constituted amino acids, as well as nucleic acid, trehaolse di-mycolate, and bacterial endotoxins. These results demonstrated that the prepared SMP-105 was of sufficient quality for research into the chemistry, bioactivity, and structure-activity relationship of CWS.
- 公益社団法人日本薬学会の論文
- 2007-06-01
著者
-
Sunagawa Makoto
Faculty Of Pharmaceutical Sciences Teikyo Heisei University
-
UENISHI Yuko
Technology Research & Development Center, Dainippon Sumitomo Pharma Co., Ltd.
-
OKADA Takashi
Technology Research & Development Center, Dainippon Sumitomo Pharma Co., Ltd.
-
OKABE Seiji
Ehime Plant, Dainippon Sumitomo Pharma Co., Ltd.
-
Uenishi Yuko
Technology Research & Development Center Dainippon Sumitomo Pharma Co. Ltd.
-
Okada Takashi
Technology Research & Development Center Dainippon Sumitomo Pharma Co. Ltd.
-
Okabe Seiji
Ehime Plant Dainippon Sumitomo Pharma Co. Ltd.